[First published on April 22, 2024]
IMPORTANT ARTICLE:
The non-existent Covid Pandemic was "announced" in September 2019.
***
Reviewing BioNTech's Disclosure of Classes of Share Capital for the year ended December 31, 2019, I noticed the following:
On August 30, 2019, BioNTech entered into agreements with the Bill & Melinda Gates Foundation (BMGF). BMGF agreed to purchase 3,038,674 ordinary shares with nominal amount of k€ 3,039 of BioNTech for a total of k€49,864 (k$55,000). These agreements require BioNTech to perform certain research and development activities to advance the development of products for the prevention and treatment of HIV and tuberculosis. In the event of a breach of the underlying conditions, including such research and development activities, BMGF has the right to sell its shares back to BioNTech at the initial share price or fair market value, whichever is higher, subject to certain conditions. BioNTech's ability to pay dividends is also limited under the terms of these agreements.Less than two years after the Gates Foundation purchased the stock (pre-IPO) at $18 per share, it peaked on Aug. 6, 2021 at $389. At that price, the Foundation's $55 million investment was worth $1,182,044,186.00 ($1.182 billion).













Comment: A very partial list: